This announcement is a separate document:
上海荣正企业咨询服务（集团）股份有限公司关于诺诚健华医药有限公司2023年科创板限制性股票激励计划首次授予部分第一个归属期符合归属条件之独立财务顾问报告
Shanghai Rongzheng Enterprise Consulting Services (Group) Co., Ltd.'s independent financial advisor report on the first vesting period of Innocare Pharmaceutical Co., Ltd.'s 2023 STAR Market restricted stock incentive plan that meets the attribution conditions for the first time.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.